skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management

Review

(2665) Views  (936) Full article downloads

Authors: Ann Gramza, Kathryn G Schuff

Published Date January 2009 Volume 2008:1 Pages 87 - 101
DOI: http://dx.doi.org/10.2147/OTT.S3480

Ann Gramza1, Kathryn G Schuff2

1Division of Medical Oncology, Oregon Health and Science University, Portland, OR USA; 2Division of Endocrinology, Oregon Health and Science University, Portland, OR USA

Abstract: Radioiodine (RAI) ablation following thyroidectomy is standard of care treatment for patients with intermediate or high risk differentiated thyroid cancer. Traditionally, this has been achieved by forgoing thyroid hormone replacement postoperatively, allowing endogenous thyroid stimulating hormone (TSH) levels to rise. This rise in TSH provides the stimulus for RAI uptake by the thyroid remnant, but is associated with clinical hypothyroidism and its associated morbidities. Recombinant human TSH (rhTSH, thyrotropin alfa [Thyrogen®], Genzyme Corporation, Cambridge, MA, USA) was developed to provide TSH stimulation without withdrawal of thyroid hormone and clinical hypothyroidism. Phase III studies reported equivalent detection of recurrent or residual disease when rhTSH was used compared with thyroid hormone withdrawal (THW). These trials led to its approval as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without RAI imaging in the surveillance of patients with differentiated thyroid cancer. Recently, rhTSH was given an indication for adjunctive preparation for thyroid remnant ablation after phase III studies demonstrated comparable outcomes for rhTSH preparation when compared with THW. Importantly, rhTSH stimulation has been found to be safe, well tolerated, and to result in improved quality of life. Here, we review the efficacy and tolerability studies leading to the approval for the use of rhTSH in well-differentiated thyroid cancer management.

Keywords: recombinant human thyroid stimulating hormone, thyroid cancer, radioiodine, ablation, Thyrogen®, thyrotropin alfa








Readers of this article also read:

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer